Check Out Nutriband (NASDAQ: NTRB) While It’s Still Early—It’s Topping Today’s Watchlist

*Sponsored by Nutriband Inc. Just Announced! Nutriband Inc. (NASDAQ: NTRB) Just Hit Our Radar This Morning—Wednesday, April 30, 2025. (NTRB) Comes Backed By Several Potential Catalysts Including: Analyst’s $13 Target Suggests 150% Upside Potential From Yesterday’s $5.60 Open. There’s Under 5.2M Shares Listed In The Float—Which Could Signal The Potential For Significant Swings If Demand Shifts. (NTRB) Is Currently Trending Above Its 5-Day ($5.46) And 20-Day ($5.22) Moving Averages—Which Could Show The Potential For Bullish Momentum. Check Out (NTRB) While It’s Still Early… April 30, 2025 Dear Reader, A little-known biotech is stepping up to battle the opi-oid crisis with a patch that could halt abuse in its tracks! This isn’t just a lab breakthrough—it’s a fierce mission to save lives! Nutriband Inc. (NASDAQ: NTRB), led by CEO Gareth Sheridan and his dedicated team, is behind AVERSA™, a revolutionary force in pain management. With just 5.2M shares in its float, the potential for significant volatility and big swings could be on the table. As of yesterday, (NTRB) is trending above its 5-day ($5.46) and 20-day ($5.22) moving averages, and Noble Capital’s Robert Leboyer forecasting a $13 target, which suggests 150% upside potential from its recent open of around $5.60. Get ready—here’s why (NTRB) just hit the top of our watchlis—we will have all eyes on this, tomorrow, April 30, 2025! Momentum has been building fast, and the latest developments only reinforce why this name continues to rise through the ranks. From breakthrough innovation to global expansion, this company is stacking milestones worth paying close attention to. Why Nutriband Inc. (NASDAQ: NTRB) Is Topping Our Watchlist… Strong Patents Around the World: (NTRB)’s AVERSA™ technology, which prevents opi-oid and stimulant abuse, is protected by patents in 46 countries. On February 7, 2025, the U.S. Patent Office approved a new patent (application 18/369,241) for AVERSA™, making its U.S. protection even stronger.  On April 11, 2025, a patent in Macao (number J/9010) added to this global shield, covering countries like the U.S., Europe, Japan, and China.  These patents, good until 2035, protect AVERSA™ fen-tan-yl, Buprenorphine, and Methylphenidate, making (NTRB) a leader in safe transdermal products. Major Partnership with Kindeva: On February 13, 2025, Nutriband teamed up with Kindeva top expert in dr-ug-device systems.  This exclusive deal combines Kindeva’s FDA-approved fen-tan-yl patch with (NTRB)’s AVERSA™ technology, aiming for an FDA investigational (IND) filing by mid-2025.  The partnership splits costs and includes milestone payments, helping Nutriband move faster toward launching the world’s first abuse-deterrent fen-tan-yl patch. Big Market Potential: Health Advances, a trusted healthcare consulting firm, predicts AVERSA™ fen-tan-yl could earn $80–200M in peak U.S. sales, thanks to its competitive price compared to other fen-tan-yl patches. AVERSA™ Buprenorphine, another potential first-of-its-kind product, could bring in $70–130M yearly. These numbers, based on 2022 and 2023 research, show a huge need for safer pain management, backed by 2022 CDC opi-oid guidelines. Solid Fiscal Position: (NTRB) has a strong financial foundation. As of October 31, 2024, it had $5.7M in cash and $12.55M in total assets, with only $1.32M in liabilities.  This means Nutriband can keep funding its projects and hit important FDA goals without fiscal stress. Smart Branding Moves: On April 4, 2025, (NTRB) partnered with Charlotte FC, a Major League Soccer team, to promote its AI Tape and AVERSA™ brands. Based in its North Carolina facility, this deal boosts Nutriband’s visibility and ties it to the local community.  On February 11, 2025, Olympic silver medalist Anastasia Nichita joined Nutriband’s Product Advisory Board to help grow its consumer products, like AI Tape, a kinesiology tape with healing ingredients. Behind the Scenes: A Leader’s Clear Vision: In a December 2024 letter to shareholders, CEO Gareth Sheridan shared his passion: “Your support drives our mission to make patients safer with innovative transdermal technology.”  He highlighted the Kindeva partnership as a key step for AVERSA™ fen-tan-yl, which could change how opioids are used safely.  Sheridan also noted that Nutriband might skip Phase 2 and 3 clinical trials because Kindeva’s fen-tan-yl patch is already FDA-approved, which could speed up the process.  His clear focus and confidence show a leader ready to deliver results. Why Nutriband Is Worth Watching: Nutriband Inc. (NASDAQ: NTRB) is a biotech leader fighting the opioid crisis with smart solutions and determination.  Its worldwide patents, strong Kindeva partnership, and $80–200M sales potential for AVERSA™ fen-tan-yl show a company ready to shine.  Here’s 7 Reasons Why Nutriband Inc. (NASDAQ: NTRB) is Topping Our Watchlist This Morning… 1. Analyst Coverage: Noble Capital’s Robert Leboyer set a $13 target, which suggests a 150% upside potential from yesterday’s $5.60 open, reflecting strong confidence in (NTRB)’s growth potential. 2. Low Float: With a float of under 5.2M shares, (NTRB)’s low availability could lead to the potential for significant volatility and big swings if demand starts to shift. 3. Technical Momentum: As of recent data, (NTRB) is trending above its 5-day ($5.46) and 20-day ($5.22) moving averages, showing short-term strength, though it remains below its 50-day average ($6.14), hinting at the potential for bullish momentum. 4. Market Potential: Health Advances forecasts AVERSA™ fen-tan-yl could achieve $80–200M in peak U.S. sales and AVERSA™ Buprenorphine $70–130M annually, driven by the urgent need for safer pain management solutions, as supported by 2022 CDC opi-oid guidelines. 5. Strategic Partnership: On February 13, 2025, (NTRB) secured an exclusive deal with Kindeva to develop AVERSA™ fen-tan-yl, targeting an FDA investigational filing by mid-2025. 6. Innovative Technology: (NTRB)’s AVERSA™ transdermal patch, infused with aversive agents like Bitrex®, aims to prevent opi-oid misuse while delivering pain relief, positioning it as a pioneering solution in addressing the opi-oid crisis. 7. Robust Intellectual Property Portfolio: AVERSA™ is backed by patents in 46 countries, including a U.S. patent allowance on February 7, 2025, and a Macao patent (J/9010) granted by April 11, 2025, ensuring protection through 2035 for products like AVERSA™ fen-tan-yl and Buprenorphine. Get (NTRB) On Your Screen While It’s Still Early… Nutriband Inc. (NASDAQ: NTRB) is carving a bold path in biotech, leveraging its AVERSA™ technology to address the opi-oid crisis with precision and innovation.  With a low float of under 5.2M shares, technical strength above key moving averages, and a $13 target from Noble Capital which suggests 150% upside potential, (NTRB) poised for attention.  Its global patents across 46 countries, exclusive Kindeva partnership, and Health Advances’ projections of up to $200M in peak U.S. sales for AVERSA™ fen-tan-yl underscore its potential to reshape pain management.  Nutriband Inc. (NASDAQ: NTRB) is on track for its mid-2025 FDA milestone, making it one little-known company to keep on your radar. We have (NTRB) on our screens right now. Get (NTRB) on your radar while it’s still early. My next update should be out to you very shortly—keep an eye out for it. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 04/29/2025 and ending on 04/30/2025 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Headline Media LLC has been paid thirty thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US). Neither Headline Media LLC, TD Media LLC and their member own shares of (NTRB:US). Please see important disclosure information here: https://marketcrux.com/disclosure/ntrb-ybhl5/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice